Citalopram

Citalopram, sold under the brand name Celexa among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 7 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Citalopram, sold under the brand name Celexa among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used to treat major depressive disorder, obsessive–compulsive disorder, panic disorder, and social anxiety disorder. The antidepressant effects may take one to four weeks to occur.

It is typically taken orally (swallowed by mouth). In some European countries, it is sometimes given intravenously (injected into a vein) to initiate treatment, before switching to the oral route of administration for continuation of treatment. It has also been used intravenously in other parts of the world in some other circumstances.

Common side effects include nausea, trouble sleeping, sexual problems, shakiness, feeling tired, and sweating. In some patients, sexual dysfunction may persist even after the drug is discontinued, a condition known as post-SSRI sexual dysfunction; regulatory agencies including the European Medicines Agency and Health Canada have recommended that citalopram's product labeling warn of this risk.

Serious side effects include an increased risk of suicide in those under the age of 25, serotonin syndrome, glaucoma, and QT prolongation. Citalopram was approved for medical use in the United States in 1998. It is on the World Health Organization's List of Essential Medicines.

It is available as a generic medication.…

Citalopram, sold under the brand name Celexa among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used to treat major depressive disorder, obsessive–compulsive disorder, panic disorder, and social anxiety disorder. The antidepressant effects may take one to four weeks to occur.

It is typically taken orally (swallowed by mouth). In some European countries, it is sometimes given intravenously (injected into a vein) to initiate treatment, before switching to the oral route of administration for continuation of treatment. It has also been used intravenously in other parts of the world in some other circumstances.

Common side effects include nausea, trouble sleeping, sexual problems, shakiness, feeling tired, and sweating. In some patients, sexual dysfunction may persist even after the drug is discontinued, a condition known as post-SSRI sexual dysfunction; regulatory agencies including the European Medicines Agency and Health Canada have recommended that citalopram's product labeling warn of this risk.

Serious side effects include an increased risk of suicide in those under the age of 25, serotonin syndrome, glaucoma, and QT prolongation. Citalopram was approved for medical use in the United States in 1998. It is on the World Health Organization's List of Essential Medicines.

It is available as a generic medication. In 2023, it was the 43rd most commonly prescribed medication in the United States, with more than 14 million prescriptions.

Medical uses

(size 19.05 mm/0.75 in)

Depression

In the United States, citalopram is approved to treat major depressive disorder. Citalopram appears to have comparable efficacy and superior tolerability relative to other antidepressants.

In the National Institute for Health and Clinical Excellence ranking of ten antidepressants for efficacy and cost-effectiveness, citalopram is fifth in effectiveness (after mirtazapine, escitalopram, venlafaxine, and sertraline) and fourth in cost-effectiveness. Evidence for the effectiveness of citalopram for treating depression in children is uncertain.

Adverse effects

Citalopram theoretically causes side effects by increasing the concentration of serotonin in other parts of the body (e.g., the intestines). Other side effects, such as increased apathy and emotional flattening, may be caused by the decrease in dopamine release associated with increased serotonin.

Citalopram is also a mild antihistamine, which may be responsible for some of its sedating properties. Other common side effects of citalopram include drowsiness, insomnia, nausea, weight changes (usually weight gain), increase in appetite, vivid dreaming, frequent urination, dry mouth, increased sweating, trembling, diarrhea, excessive yawning, severe tinnitus, and fatigue.

Less common side effects include bruxism, vomiting, cardiac arrhythmia, blood pressure changes, dilated pupils, anxiety, mood swings, headache, hyperactivity and dizziness. Rare side effects include convulsions, hallucinations, severe allergic reactions and photosensitivity. If sedation occurs, the dose may be taken at bedtime rather than in the morning.

Some data suggest citalopram may cause nightmares. Citalopram is associated with a higher risk of arrhythmia than other SSRIs. Citalopram and other SSRIs can induce a mixed state, especially in those with undiagnosed bipolar disorder.

One of the other rare side effects of citalopram is visual snow syndrome which does not resolve after the discontinuation of the medicine.

Suicidality

In the United States, citalopram carries a boxed warning stating it may increase suicidal thinking and behavior in those under age 24. Citalopram has a ~6-fold higher affinity for H1 histamine receptors than (S)-citalopram (K i = 257nM vs 1500nM), though the clinical significance of this difference is unknown. Both citalopram and escitalopram have similar affinities for the σ1 receptor (K i = 50nM).

Metabolism

Citalopram is metabolized in the liver mostly by CYP2C19, but also by CYP3A4 and CYP2D6. Metabolites desmethylcitalopram and didesmethylcitalopram are significantly less energetic and their contribution to the overall action of citalopram is negligible. The half-life of citalopram is about 35 hours.

Approximately 80% is cleared by the liver and 20% by the kidneys. The elimination process is slower in the elderly and in patients with liver or kidney failure. With once-daily dosing, steady plasma concentrations are achieved in about a week.

Potent inhibitors of CYP2C19 and 3A4 might decrease citalopram clearance. Tobacco smoke exposure was found to inhibit the biotransformation of citalopram in animals, suggesting that the elimination rate of citalopram is decreased after tobacco smoke exposure. After intragastric administration, the half-life of the racemic mixture of citalopram was increased by about 287%.

History

Citalopram was first synthesized in 1972 by chemist Klaus Bøgesø and his research group at the pharmaceutical company Lundbeck and was first marketed in 1989 in Denmark. It was first marketed in the US in 1998. The original patent expired in 2003, allowing other companies to legally produce and market generic versions.

Brand names

Citalopram is sold under these brand names: Akarin (Denmark, Nycomed) C Pram S (India) Celapram (Australia, New Zealand), Celexa (U.S. and Canada, Forest Laboratories, Inc.) Celica (Australia) Ciazil (Australia, New Zealand) Cilate (South Africa) Cilift (South Africa) Cipram (Denmark, Turkey, H. Lundbeck A/S) Cipramil (Australia, Brazil, Belgium, Chile, Finland, Germany, Netherlands, Iceland, Ireland, Israel, New Zealand, Norway, Russia, South Africa, Sweden, United Kingdom) Cipraned, Cinapen (Greece) Ciprapine (Ireland) Ciprotan (Ireland) Citabax, Citaxin (Poland) Cital (Poland) Citalec (Czech Republic, Slovakia) Citalex (Iran, Serbia) Citalo (Australia, Egypt, Pakistan) Citalopram (Canada, Denmark, Finland, Germany, Ireland, The Netherlands, New Zealand, Spain, Sweden, Switzerland, United Kingdom, U.S.) Citol (Russia, Turkey) Citox (Mexico) Citrol (Europe and Australia) Citta (Brazil) Dalsan (Eastern Europe) Denyl (Brazil) Depram (Egypt) Elopram (Italy) Estar (Pakistan) Humorup (Argentina) Humorap (Peru, Bolivia) Lopraxer (Greece) Oropram (Iceland, Actavis), Opra (Russia) Pram (Russia) Pramcit (Pakistan) Procimax (Brazil) Recital (Israel, Thrima Inc. for Unipharm Ltd.) Sepram (Finland) Seropram (various European countries, including the Czech Republic) Szetalo (India) Talam (Europe and Australia) Temperax (Argentina, Chile, Peru) Vodelax (Turkey) Zentius (South America, by Roemmers and Recalcine) Zetalo (India) Cipratal (Kuwait, GCC) Zylotex (Portugal)

European Commission fine

On 19 June 2013, the European Commission imposed a fine of €93.8 million on the Danish pharmaceutical company Lundbeck, plus a total of €52.2 million on several generic pharmaceutical-producing companies. This was in response to Lundbeck entering an agreement with the companies to delay their sales of generic citalopram after Lundbeck's patent on the drug had expired, thus reducing competition in breach of European antitrust law.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1374924002 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

23 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.